SCHEMBL7900446

SCHEMBL7900446

O=[N+]([O-])c1ccc(N(CCO)CCO)cc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
TDP1 Q9NUW8 3/20 0.59
TSHR P16473 1/20 0.59
ATM Q13315 2/20 0.51
KDM4E B2RXH2 1/20 0.44
NSD2 O96028 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
POLB P06746 3/20 0.41
VCAM1 P19320 2/20 0.40
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39
MMP14 P50281 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6151379 0.87 ALDH1A1 (0.63) ALDH1A1TDP1TSHRATMKDM4E
SCHEMBL7470399 0.83 MAPT (0.61) ALDH1A1TDP1TSHRKDM4ENSD2
SCHEMBL8318666 0.81 ALDH1A1 (0.63) ALDH1A1TDP1TSHRKDM4ENSD2
SCHEMBL14180498 0.80 TDP1 (0.55) ALDH1A1TDP1TSHRATMKDM4E
SCHEMBL27752508 0.79 ALDH1A1 (0.62) ALDH1A1TDP1TSHRATMKDM4E
SCHEMBL29390088 0.79 TDP1 (0.62) ALDH1A1TDP1TSHRKDM4ENSD2
SCHEMBL14174537 0.79 ALDH1A1 (0.62) ALDH1A1TDP1TSHRKDM4EPOLB
SCHEMBL127252 0.79 TDP1 (0.62) ALDH1A1TDP1TSHRKDM4ENSD2
SCHEMBL27758417 0.79 ALDH1A1 (0.58) ALDH1A1TDP1TSHRATMKDM4E
SCHEMBL1311975 0.79 ALDH1A1 (0.54) ALDH1A1TDP1TSHRKDM4ENSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277880-B1 ANTIBODY DIRECTED ENZYME PRODUG THERAPY ZENECA LIMITED (GB) 2001-08-21 US disclosed
US-5958971-A PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION ZENECA LIMITED (GB) 1999-09-28 US disclosed
EP-0651740-B1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LTD (GB) 1998-10-21 EP disclosed
US-5714148-A PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS ZENECA LIMITED (GB) 1998-02-03 US disclosed
US-5660829-A DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE ZENECA LIMITED (GB) 1997-08-26 US disclosed
US-5587161-A TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME ZENECA LIMITED (GB) 1996-12-24 US disclosed
US-5405990-A For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents ZENECA LIMITED (GB) 1995-04-11 US disclosed